|
|
Article: Eyetech Locates 'Exit' Through $935M Cash, Stock OSI Merger.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
As potential eye drug competitor Lucentis nears market, Eyetech Pharmaceuticals Inc. agreed to merge with OSI Pharmaceuticals Inc., bringing along its approved product Macugen, in a deal worth $935 million - or $20 a share, a 43 percent premium over Eyetech's closing stock price on Friday.
Shares (NASDAQ:EYET) climbed Monday more than 29 percent, or $4.14, to end the day at $18.13.
"It's a great deal, obviously, for Eyetech shareholders. They're getting a premium on [Monday's] price, which has since run up from its bottom," said Andrew McDonald, a research analyst with ThinkEquity Partners LLC in San Francisco. "Eyetech management ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cel-Sci Acquisition Inc., of the British Virgin Islands, ...
BIOWORLD Today;
August 23, 1999 ;
700+ words
... ... Corp.'s legal counsel. (See BioWorld Today, Aug. 20, 1999, p. 1 ... Bristol-Myers Squibb Co., of New York, as part of its license and ... 87 million in cash. (See BioWorld Today, Aug. 3, 1999, p. 1 ...
|
|